EconPapers    
Economics at your fingertips  
 

Estimation of COVID-19 Prevalence from Serology Tests: A Partial Identification Approach

Panos Toulis ()
Additional contact information
Panos Toulis: University of Chicago - Booth School of Business

Working Papers from Becker Friedman Institute for Research In Economics

Abstract: We propose a partial identification method for estimating disease prevalence from serology studies. Our data are results from antibody tests in some population sample, where the test parameters, such as the true/false positive rates, are unknown. Our method scans the entire parameter space, and rejects parameter values using the joint data density as the test statistic. The proposed method is conservative for marginal inference, in general, but its key advantage over more standard approaches is that it is valid in ï¬ nite samples even when the underlying model is not point identified. Moreover, our method requires only independence of serology test results, and does not rely on asymptotic arguments, normality assumptions, or other approximations. We use recent Covid-19 serology studies in the US, and show that the parameter confidence set is generally wide, and cannot support deï¬ nite conclusions. Specifically, recent serology studies from California suggest a prevalence anywhere in the range 0%-2% (at the time of study), and are therefore inconclusive. However, this range could be narrowed down to 0.7%-1.5% if the actual false positive rate of the antibody test was indeed near its empirical estimate (~0.5%). In another study from New York State, Covid-19 prevalence is confidently estimated in the range 13%-17% in mid-April of 2020, which also suggests significant geographic variation in Covid-19 exposure across the US. Combining all datasets yields a 5%-8% prevalence range. Our results overall suggest that serology testing on a massive scale can give crucial information for future policy design, even when such tests are imperfect and their parameters unknown.

Keywords: partial identification; disease prevalence; serology tests; Covid-19 (search for similar items in EconPapers)
JEL-codes: C12 C14 I10 (search for similar items in EconPapers)
Pages: 36 pages
Date: 2020
New Economics Papers: this item is included in nep-hea
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (1) Track citations by RSS feed

Downloads: (external link)
https://repec.bfi.uchicago.edu/RePEc/pdfs/BFI_WP_202054_Revised.pdf (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:bfi:wpaper:2020-54_revised

Access Statistics for this paper

More papers in Working Papers from Becker Friedman Institute for Research In Economics Contact information at EDIRC.
Bibliographic data for series maintained by Toni Shears ().

 
Page updated 2021-10-13
Handle: RePEc:bfi:wpaper:2020-54_revised